Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 14

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 14
---
 the Japanese yen as compared to the nine-month period ended December 31, 2023.

<div align='center'>7</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

Core Selling, General and Administrative (SG&A) Expenses

Core SG&A expenses were JPY 809.2 billion (JPY +40.2 billion and +5.2% AER, +0.2% CER). The increase was mainly due to the depreciation of the Japanese yen.

#### Core Research and Development (R&D) Expenses
Core R&D expenses were JPY 514.3 billion (JPY -19.7 billion and -3.7% AER, -8.5% CER). The decrease was mainly due to lower expenses attributable to termination of development programs such as modakafusp alfa (TAK-573) and EXKIVITY (for non-small cell lung cancer) partially offset by the depreciation of the Japanese yen.

#### Core Net Profit for the Period
Core Net Profit for the Period was JPY 699.1 billion ( JPY +55.4 billion and +8.6% AER, +1.9% CER) and Core Net Profit attributable to owners of the Company was JPY 698.9 billion (JPY +55.3 billion and +8.6% AER, +1.9% CER) and are calculated from Core Operating Profit as below:

|                                                                           |     |           |     |          |        |     |           |     |          |         |     |     |     |       |     |       |   |     |     |       | Billion JPY or percentage |
|                                                                           |     | FY2023 Q3 |     |          |        |     | FY2024 Q3 |     |          |         |     | AER |     |       |     |       |   | CER |     |       |                           |
| Amount of Change                                                          |     |           |     | % Change |        |     |           |     | % Change |         |     |     |     |       |     |       |   |     |     |       |                           |
| Core operating profit                                                     |     |           |     |          |  865.6 |     |           |     |          | 1